 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 653 | 回復(fù): 3 | |||
| 本帖產(chǎn)生 1 個 翻譯EPI ，點擊這里進行查看 | |||
| 當前只顯示滿足指定條件的回帖，點擊這里查看本話題的所有回帖 | |||
霜葉專家顧問
|
[求助]
翻譯一段摘要，謝謝
|
||
|
OBJECTIVES: Some large population-based studies have reported a dose-related increased risk of cataracts and glaucoma associated with use of inhaled corticosteroids (ICS) in patients with asthma or chronic obstructive pulmonary disease (COPD). We evaluated the association between use of ICS-containing products, specifically fluticasone propionate/salmeterol fixed-dose combination (FSC), and incidence of cataracts and glaucoma among patients with COPD in a large electronic medical record database in the United Kingdom. METHODS: We identified a cohort of patients aged 45 years and over with COPD in the General Practice Research Database (GPRD) between 2003 and 2006. Cases of incident cataracts or glaucoma were defined based on diagnosis and procedure codes and matched to controls from the risk set to estimate odds ratios (OR) and 95% confidence intervals (CI). The association with FSC or ICS exposure was modeled using conditional logistic regression. Medication exposure was assessed with respect to recency, duration, and number of prescriptions prior to the index date. Average daily dose was defined as none, low (1-250 mcg), medium (251-500 mcg), high (501-1000 mcg), or very high (1001+ mcg) using fluticasone propionate (FP) equivalents. RESULTS: We identified 2941 incident cataract cases and 327 incident glaucoma cases in the COPD cohort (n = 53,191). FSC or ICS prescriptions were not associated with risk of incident cataracts or glaucoma for any exposure category, after adjusting for confounders. We observed a lack of a dose response in all analyses, where low dose was the reference group. The odds of cataracts associated with FSC dose were medium OR: 1.1 (95% CI: 0.9-1.4); high OR: 1.2 (95% CI: 0.9-1.5); and very high OR: 1.2 (95% CI: 0.9-1.7). The odds of glaucoma associated with FSC dose: medium OR: 1.0 (95% CI: 0.5-2.1); high OR: 1.0 (95% CI: 0.5-2.0); and very high OR: 1.0 (95% CI: 0.4-2.8). CONCLUSIONS: FSC or other ICS exposure was not associated with an increased odds of cataracts or glaucoma, nor was a dose-response relationship observed in this population-based nested case-control study of COPD patients in the United Kingdom. |
回復(fù)此樓» 猜你喜歡
調(diào)劑推薦
已經(jīng)有10人回復(fù)
-
0710生物學考研調(diào)劑
已經(jīng)有4人回復(fù)
-
291求調(diào)劑
已經(jīng)有17人回復(fù)
-
0703化學求調(diào)劑，各位老師看看我�。。�
已經(jīng)有6人回復(fù)
-
311求調(diào)劑
已經(jīng)有10人回復(fù)
-
化學308分調(diào)劑
已經(jīng)有14人回復(fù)
-
一志愿廈門大學化學學碩307求調(diào)劑
已經(jīng)有11人回復(fù)
-
材料調(diào)劑
已經(jīng)有4人回復(fù)
-
【求調(diào)劑】085601材料工程專碩 | 總分272 |
已經(jīng)有9人回復(fù)
-
286分調(diào)劑
已經(jīng)有15人回復(fù)
vigor222
管理員
|
本帖內(nèi)容被屏蔽 |
3樓2013-03-26 15:51:34
houbingxiao
版主
- 翻譯EPI: 1
- 應(yīng)助: 2 (幼兒園)
- 金幣: 1672.5
- 帖子: 99
- 在線: 31.4小時
- 蟲號: 2326487
- 注冊: 2013-03-07
- 性別: MM
- 專業(yè): 蛋白質(zhì)組學
樓主你可以考慮多給點金子來吸引有才之士~~~~ 
2樓2013-03-26 15:43:16
Rio2016
管理員
- 翻譯EPI: 72
- 應(yīng)助: 28 (小學生)
- 貴賓: 0.013
- 金幣: 3301.7
- 散金: 25
- 紅花: 6
- 帖子: 300
- 在線: 243.3小時
- 蟲號: 1910117
- 注冊: 2012-07-25
- 專業(yè): 抗腫瘤藥物藥理
【答案】應(yīng)助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
霜葉: 金幣+15, 翻譯EPI+1, ★★★★★最佳答案, 非常感謝，剩余的麻煩幫我再翻譯，謝謝啦 我已追加金幣 2013-03-26 18:15:44
霜葉(phu_grassman代發(fā)): 金幣+10 2013-04-14 09:52:13
霜葉: 金幣+15, 翻譯EPI+1, ★★★★★最佳答案, 非常感謝，剩余的麻煩幫我再翻譯，謝謝啦 我已追加金幣 2013-03-26 18:15:44
霜葉(phu_grassman代發(fā)): 金幣+10 2013-04-14 09:52:13
|
OBJECTIVES: 目標： Some large population-based studies have reported a dose-related increased risk of cataracts and glaucoma associated with use of inhaled corticosteroids (ICS) in patients with asthma or chronic obstructive pulmonary disease (COPD). We evaluated the association between use of ICS-containing products, specifically fluticasone propionate/salmeterol fixed-dose combination (FSC), and incidence of cataracts and glaucoma among patients with COPD in a large electronic medical record database in the United Kingdom. 一些基于大量人群的研究報告稱，在患有哮喘或慢性阻塞性肺疾病(COPD)的病人發(fā)生白內(nèi)障和青光眼的風險，與他們使用吸入式糖皮質(zhì)激素(ICS)存在劑量遞增性。我們評估了使用含吸入式糖皮質(zhì)激素(ICS)產(chǎn)品，特別是丙酸氟替卡松/沙美特羅定量組合(FSC)，與大英帝國一個大型電子醫(yī)療記錄數(shù)據(jù)庫中慢性阻塞性肺病患者 白內(nèi)障和青光眼發(fā)生率的關(guān)系。 METHODS: 方法： We identified a cohort of patients aged 45 years and over with COPD in the General Practice Research Database (GPRD) between 2003 and 2006. Cases of incident cataracts or glaucoma were defined based on diagnosis and procedure codes and matched to controls from the risk set to estimate odds ratios (OR) and 95% confidence intervals (CI). 在研究數(shù)據(jù)庫(GPRD)中處于2003到2006年這段期間里，我們發(fā)現(xiàn)了一個年齡為45歲且患有COPD的同期組群。白內(nèi)障或青光眼的發(fā)生病例通過診斷和程序編碼來確定，并結(jié)合通過控制風險設(shè)定來計算比值比（OR）和置信區(qū)間為95%。 先這么多吧 、、確實不好翻譯  |
4樓2013-03-26 17:10:46
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 調(diào)劑 +5 | 好好讀書。 2026-03-28 | 7/350 |
|
|---|---|---|---|---|
|
|
[考研] 材料0856 英一數(shù)二 323 求調(diào)劑 +9 | 袁sy 2026-04-01 | 9/450 |
|
|
[考研] 安徽大學專碩生物與醫(yī)藥專業(yè)(086000)324分，英語已過四六級，六級521，求調(diào)劑 +10 | 美味可樂雞翅 2026-03-26 | 12/600 |
|
|
|
[考研] 考研材料工程351分調(diào)劑 +5 | 整個好的 2026-03-31 | 5/250 |
|
|
|
[考研] 【調(diào)劑】一志愿廈大生物與醫(yī)藥調(diào)劑 +3 | Echo蝦米 2026-03-31 | 3/150 |
|
|
|
[考研] 求調(diào)劑：085600材料與化工，考材科基，總分319 +17 | 678lucky 2026-03-31 | 21/1050 |
|
|
|
[考研] 318求調(diào)劑 +3 | 篤行致遠. 2026-03-31 | 3/150 |
|
|
|
[考研] 08開頭看過來�。�！ +3 | wwwwffffff 2026-03-31 | 5/250 |
|
|
|
[考研] 材料工程專碩求調(diào)劑 +10 | hyl3153942 2026-03-29 | 10/500 |
|
|
|
[考研] 本科211生物醫(yī)學工程085409求調(diào)劑339分 +7 | 里子木yy 2026-03-29 | 7/350 |
|
|
|
[考研] 274求調(diào)劑 +6 | xiao愛同學 2026-03-30 | 6/300 |
|
|
|
[考研] 085600材料與化工329分求調(diào)劑 +5 | 這是有太陽哇 2026-03-25 | 5/250 |
|
|
|
[考研] 調(diào)劑 +4 | GK72 2026-03-30 | 4/200 |
|
|
|
[考研] 279求調(diào)劑 +12 | j的立方 2026-03-29 | 12/600 |
|
|
|
[考研] 327求調(diào)劑 +5 | 小卡不卡. 2026-03-29 | 5/250 |
|
|
|
[考研] 297求調(diào)劑 +17 | 田洪有 2026-03-26 | 18/900 |
|
|
|
[考研] 310求調(diào)劑 +10 | 爭取九點睡 2026-03-30 | 10/500 |
|
|
|
[考研] 085600，材料與化工321分求調(diào)劑 +10 | 大饞小子 2026-03-28 | 10/500 |
|
|
|
[考研] 292求調(diào)劑 +4 | 求求了收下我吧?/a> 2026-03-26 | 4/200 |
|
|
|
[考研] 環(huán)境專碩324分求調(diào)劑推薦 +5 | 軒小寧—— 2026-03-26 | 5/250 |
|